Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

BUY
$6.61 - $8.72 $142,531 - $188,029
21,563 New
21,563 $177,000
Q4 2021

Feb 10, 2022

SELL
$4.69 - $7.4 $69,139 - $109,090
-14,742 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.12 - $6.89 $75,479 - $101,572
14,742 New
14,742 $91,000

Others Institutions Holding AVEO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About AVEO PHARMACEUTICALS, INC.


  • Ticker AVEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,676,000
  • Description
  • AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...
More about AVEO
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.